Traffic at the Cognis Nutrition & Health booth at the SupplySide West trade show is expected to be brisk as dietary supplement and functional food manufacturers discover the benefits of three new, non-GMO natural health ingredients Cognis is launching — Covi-ox? T-95 EU natural mixed tocopherols, Vegapure? F40 WDP E water dispersible natural plant sterols, Xangold? 20% natural lutein ester beadlets.
CLA may serve critical role in preventing weight and fat gain during year-end holidays and with normal aging. Avoiding ‘weight creep’ from turkey and sugar plums is the theme of a consumer PR campaign Cognis Nutrition & Health is rolling out in time for the holiday season based on a Tonalin? CLA study recently published online in the prestigious International Journal of Obesity. The research suggests that Tonalin? CLA could have long-term health benefits by preventing weight and fat gain commonly experienced by adults during the November-December holiday season, and in the normal aging process.
A compromised immune system makes people more prone to contracting a cold or flu, and Cognis is helping companies meet the growing demand worldwide for immunity boosting dietary supplements and functional foods. Colds and flu are the most frequent infections across all age groups. Each year, Americans suffer from one billion colds, 100,000 are hospitalized and about 36,000 die from the flu and its complications. Immune health is also a global concern with frequent colds and flu ranked as one of the top three health problems by consumers in China, India and Latin America.
Cognis will unveil its new range of high quality omega-3 fish oil products at this year?s Health Ingredients Europe event in Frankfurt. Under the brand name Omevital?, and available in ethyl ester and triglyceride forms, the new range of marine-origin oils delivers products of outstanding quality and purity, ultra-refined through state-of-the-art manufacturing processes, in accordance with Pharma GMP standards.
Schering-Plough reported data from EPIC3, a large ongoing clinical study, showing that retreatment with PEG-INTRON(R) (peginterferon alfa-2b) and REBETOL(R) (ribavirin, USP) combination therapy can result in sustained virologic response(1) (SVR) in patients with chronic hepatitis C who failed previous treatment with any alpha interferon-based combination therapy, including peginterferon regimens. In this study, 56 percent of patients who had undetectable virus (HCV-RNA) after 12 weeks went on to achieve SVR with a 48-week course of therapy. Of the first 1,354 patients retreated, approximately 38 percent had undetectable virus at week 12. Importantly, patients who did not have undetectable virus at 12 weeks had little chance of achieving SVR. Overall, 23 percent of patients achieved SVR.
A dietary supplement of oligomeric proanthocyanidins (OPC) could reduce reddening of the skin by 13 per cent, scientists from Hamburg-based Bioskin GmbH have reported, research sure to be welcomed by Europe?s burgeoning oral beauty products sector.
The Parliamentary Secretary to the Minister for Health and Ageing, Christopher Pyne, announced today the establishment of a National Collaboration on Trans Fats that will propose initiatives aimed at reducing the amount of trans fatty acids in food sold in Australia. Mr Pyne said that the National Heart Foundation of Australia, the Dietitians Association of Australia, the Australian Food and Grocery Council and Food Standards Australia New Zealand (FSANZ) would lead the initiative.
Royal Philips (NYSE: PHG, AEX: PHI) announced the availability of triplets monitoring functionality for its industry-leading line of obstetrical care fetal and maternal monitors, Avalon FM20 antepartum and Avalon FM30 intrapartum. Philips is the first company to introduce a fetal monitor that enables non-invasive triplets monitoring with a single device.
Schering-Plough Corporation (NYSE: SGP) reported that the U.S. Food and Drug Administration (FDA) has approved NOXAFIL(R) (posaconazole) Oral Suspension for the treatment of oropharyngeal candidiasis (OPC), including infections refractory to itraconazole and/or fluconazole. OPC is a fungal infection of the mouth and throat caused by the yeast Candida. NOXAFIL is a novel triazole antifungal agent discovered and developed by Schering-Plough Research Institute.
Many people with constipation are confused about the cause of their condition and its appropriate treatment with laxatives. Results of a new large-scale global survey, announced today, show that many people wrongly fear that laxatives are addictive and that their use for long periods of time actually causes constipation.1,2